Patent intelligence · US
US 12274710
Compound for regulating body weight imbalance, composition thereof and application thereof
Compound for regulating body weight imbalance, composition thereof and application thereof
Patent details — US 12274710
- Jurisdiction
- US
- Status
- granted
- Grant date
- Apr 15, 2025
- Expiration
- Apr 10, 2045
- Claims
- 15
- CPC classes
- A61K, A61K31/137, A61K31/155, A61K31/423
Quick answer
US 12274710 (Compound for regulating body weight imbalance, composition thereof and application thereof) is held by GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD. Status: granted. Granted Apr 15, 2025. Expires Apr 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Grant date
- Expiration
- Claims
- 15
- CPC classes
- A61K, A61K31/137, A61K31/155, A61K31/423, A61K31/46, A61K31/485
More from GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD
Related pharmaceutical patents in our USPTO index.
-
US 12269888
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
granted -
US 12194049
Composition for treating carbapenem antibiotic-resistant Acinetobacter baumannii infection
granted -
US 12084670
Regulating alkaloids
granted -
US 11883432
Chimeric antigen receptor system with adaptable receptor specificity
granted -
US 11865155
Plant extract obtained from Morus plant leaves which has an IC50 value to inhibit a-glucosidase I at a concentration of less than 90 uG/ml, compositions containing same, method of extraction and uses thereof
granted -
US 11667924
Increasing levels of nicotinic alkaloids in plants
granted -
US 11661459
Artificial cell death polypeptide for chimeric antigen receptor and uses thereof
granted
Frequently asked questions
What is US patent 12274710?
US 12274710 (Compound for regulating body weight imbalance, composition thereof and application thereof) is held by GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD. Status: granted. Granted Apr 15, 2025. Expires Apr 10, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 12274710?
GUANGZHOU CENTURY CLINICAL RESEARCH CO., LTD is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 39 pharmaceutical patents for this assignee.
When does US 12274710 expire?
Our index shows an expiration date of Apr 10, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.